You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 28 No. 2, February 1973 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Brain Catecholamines and Their Metabolites in Parkinsonian Patients

Treatment With Levodopa Alone or Combined With a Decarboxylase Inhibitor

Urpo K. Rinne, MD; Vesa Sonninen, MD

Arch Neurol. 1973;28(2):107-110.


Abstract

Analyses of autopsy samples of parkinsonian patients showed significantly decreased concentrations of dopamine and homovanillic acid (HVA) in extrapyramidal brain regions. Twelve patients treated with levodopa alone or combined with a decarboxylase inhibitor showed concentrations of dopamine and HVA which ranged from values corresponding to nontreated parkinsonian patients to levels above those in controls. Increase of concentration of HVA was relatively more marked than that of dopamine. There were no significant changes in the concentration of noradrenaline. Histological examination of brain samples showed no changes related to the treatment.



Author Affiliations

Turku, Finland

From the Department of Neurology, University of Turku, Turku, Finland.


Footnotes

Accepted for publication Sept 13, 1972.

Reprint requests to Department of Neurology, University of Turku, 20520 Turku 52, Finland (Dr. Rinne).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Usefulness of a dopamine transporter PET ligand [18F]beta -CFT in assessing disability in Parkinson's disease
Rinne et al.
J. Neurol. Neurosurg. Psychiatry 1999;67:737-741.
ABSTRACT | FULL TEXT  

Cerebral Blood Flow and Dementia in Parkinson's Disease
Kawabata et al.
J Geriatr Psychiatry Neurol 1991;4:194-203.
ABSTRACT  

Cerebellar Norepinephrine in Patients With Parkinson's Disease and Control Subjects
Kish et al.
Arch Neurol 1984;41:612-614.
ABSTRACT  

Brain Dopamine Turnover and the Relief of Parkinsonism
Rinne et al.
Arch Neurol 1977;34:626-629.
ABSTRACT  

Five Years' Treatment of Parkinson's Disease with Levodopa: Therapeutic Results and Survival of 100 Patients
SWEET and McDOWELL
ANN INTERN MED 1975;83:456-463.
ABSTRACT  

Clonidine in Parkinson Disease
Tarsy et al.
Arch Neurol 1975;32:134-136.
ABSTRACT  

Interaction Between Dopamine and Phospholipids: Studies of the Substantia Nigra in Parkinson Disease Patients
Riekkinen et al.
Arch Neurol 1975;32:25-27.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1973 American Medical Association. All Rights Reserved.